Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:TFX
Previous Symbol
CUSIP87936910
Phone610-225-6800
Debt
Debt-to-Equity Ratio0.83
Current Ratio2.26
Quick Ratio1.51
Price-To-Earnings
Trailing P/E Ratio25.83
Forward P/E Ratio24.97
P/E Growth2
Sales & Book Value
Annual Sales$2.15 billion
Price / Sales5.30
Cash Flow$12.2067 per share
Price / Cash Flow20.27
Book Value$53.95 per share
Price / Book4.59
Profitability
EPS (Most Recent Fiscal Year)$8.40
Net Income$152.53 million
Net Margins2.81%
Return on Equity18.04%
Return on Assets7.21%
Miscellaneous
Employees14,400
Outstanding Shares45,980,000
Market Cap$11.38 billion
OptionableOptionable
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex announced a quarterly dividend on Thursday, November 1st. Investors of record on Thursday, November 15th will be paid a dividend of $0.34 per share on Friday, December 14th. This represents a $1.36 annualized dividend and a yield of 0.55%. The ex-dividend date is Wednesday, November 14th. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) announced its earnings results on Thursday, November, 1st. The medical technology company reported $2.52 EPS for the quarter, beating the Zacks' consensus estimate of $2.41 by $0.11. The medical technology company had revenue of $609.70 million for the quarter, compared to analyst estimates of $609.05 million. Teleflex had a return on equity of 18.04% and a net margin of 2.81%. Teleflex's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.12 EPS. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
What guidance has Teleflex issued on next quarter's earnings?
Teleflex issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $9.80-9.95 for the period, compared to the Thomson Reuters consensus estimate of $9.81. The company issued revenue guidance of $2436-2457.5 million, compared to the consensus revenue estimate of $2.46 billion.
What price target have analysts set for TFX?
9 equities research analysts have issued 1-year target prices for Teleflex's stock. Their forecasts range from $255.00 to $317.00. On average, they anticipate Teleflex's share price to reach $291.6667 in the next year. This suggests a possible upside of 17.9% from the stock's current price. View Analyst Price Targets for Teleflex.
What is the consensus analysts' recommendation for Teleflex?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex.
Has Teleflex been receiving favorable news coverage?
Press coverage about TFX stock has trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Teleflex earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Penumbra (PEN), Integra Lifesciences (IART), Novocure (NVCR), Cantel Medical (CMD) and Merit Medical Systems (MMSI).
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Liam J. Kelly, Pres, CEO & Director (Age 51)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 56)
- Mr. Thomas Anthony Kennedy, Sr. VP of Global Operations (Age 55)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 51)
- Mr. John R. Deren, VP & Chief Accounting Officer
Who are Teleflex's major shareholders?
Teleflex's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.86%), Vanguard Group Inc (8.66%), Atlanta Capital Management Co. L L C (5.76%), Select Equity Group L.P. (3.42%), FMR LLC (2.92%) and William Blair Investment Management LLC (2.08%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, Gretchen R Haggerty, Jeffrey A Graves, John Deren, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Institutional Ownership Trends for Teleflex.
Which institutional investors are selling Teleflex stock?
TFX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Select Equity Group L.P., Marshall Wace North America L.P., The Manufacturers Life Insurance Company , Marshall Wace LLP, Morgan Stanley, Citadel Advisors LLC and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, George Babich Jr, John Deren, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Insider Buying and Selling for Teleflex.
Which institutional investors are buying Teleflex stock?
TFX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Bessemer Group Inc., Atlanta Capital Management Co. L L C, William Blair Investment Management LLC, Russell Investments Group Ltd., BlackRock Inc., Jennison Associates LLC and Scout Investments Inc.. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer and Gretchen R Haggerty. View Insider Buying and Selling for Teleflex.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $247.43.
How big of a company is Teleflex?
Teleflex has a market capitalization of $11.38 billion and generates $2.15 billion in revenue each year. The medical technology company earns $152.53 million in net income (profit) each year or $8.40 on an earnings per share basis. Teleflex employs 14,400 workers across the globe.
What is Teleflex's official website?
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (NYSE TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
